NanOlogy LLC presents clinical research involving its large surface area microparticle investigational drugs at the DDW 2023 poster presentation and ASCO Annual Meeting. The DDW poster presentation discusses intracystic injection of LSAM-PTX for chemoablation of Intraductal Papillary Mucinous Neoplasms, which reduces cyst volume and surface area, morphological changes, and loss of pathogenic mutations. It is suggested that further clinical research is necessary in nonsurgical high-risk patients due to a lack of approved treatments to decrease the risk for progression to pancreatic cancer. The ASCO abstract publication reviews the safety of both investigational drugs in combination with SOC therapies across seven clinical trials totaling 156 patients. Local treatment with LSAM-PTX or LSAM-DTX has potential benefits over standard-of-care therapies by increasing tumor dwell time and reducing systemic toxicities.
Additional sentence: NanOlogy's proprietary particle engineering technology platform aims to maximize drug concentration within tumors while minimizing systemic toxicity, improving treatment for solid tumors such as pancreas, lung, bladder, ovarian cancers among others.